REFERENCES
- Kaufmann M., Hortobagyi G. N., Goldhirsch A., et al. Recommendations from an inter national expert panel on the use of neoadjuvant (primary) systemic treatment of oper able breast cancer: an update. J Clin Oncol Apr 20, 2006; 24(12)1940–1949
- Fisher B., Bryant J., Wolmark N., et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol Aug, 1998; 16(8)2672–2685
- Kuerer H. M., Newman L. A., Smith T. L., et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol Feb, 1999; 17(2)460–469
- Bear H. D., Anderson S., Brown A., et al. National Surgical Adjuvant Breast and Bowel Project Protocol B-27. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol Nov 15, 2003; 21(22)4165–4174
- Buzdar A. U., Ibrahim N. K., Francis D., et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol Jun 1, 2005; 23(16)3676–3685
- Buzdar A. U., Valero V., Theriault R. L., et al. Pathological complete response to chemother apy is related to hormone receptor status. San Antonio Breast Cancer Symposium 2003, abstract 302
- Rouzier R., Perou C. M., Symmans W. F., et al. Breast cancer molecular subtypes respond dif ferently to preoperative chemotherapy. Clin Cancer Res Aug 15, 2005; 11(16)5678–5685
- Burstein H. J., Harris L. N., Gelman R., et al. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol Jan 1, 2003; 21(1)46–53
- Eiermann W., Paepke S., Appfelstaedt J., et al. Letrozole Neo-Adjuvant Breast Cancer Study Group. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol Nov, 2001; 12(11)1527–1532
- Cataliotti L., Buzdar A. U., Noguchi S., et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative “Arimidex” Compared to Tamoxifen (PROACT) trial. Cancer May 15, 2006; 106(10)2095–2103
- Smith I. E., Dowsett M., Ebbs S. R., et al. IMPACT Trialists Group. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol. Aug 1, 2005; 23(22)5108–5116
- Wedam S. B., Low J. A., Yang S. X., et al. Antiangiogenic and antitumor effects of bevacizu-mab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol Feb 10, 2006; 24(5)769–777
- Buzdar A. U., Singletary S. E., Theriault R. L., et al. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol Nov, 1999; 17(11)3412–3417
- Ellis M. J., Coop A., Singh B., et al. Letrozole is more effective neoadjuvant endocrine therapy than amoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol Sep 15, 2001; 19(18)3808–3816
- Dowsett M., Ebbs S. R., Dixon J. M., et al. Biomarker changes during neoadjuvant anastro zole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer—a study from the IMPACT trialists. J Clin Oncol Apr 10, 2005; 23(11)2477–2492
- Archer C. D., Parton M., Smith I. E., et al. Early changes in apoptosis and proliferation fol lowing primary chemotherapy for breast cancer. Br J Cancer Sep 15, 2003; 89(6)1035–1041
- Mohsin S. K., Weiss H. L., Gutierrez M. C., et al. Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol Apr 10, 2005; 23(11)2460–2468
- Gianni L., Zambetti M., Clark K, et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol Oct 10, 2005; 23(29)7265–7277
- Chang J. C., Wooten E. C., Tsimelzon A., et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 2003; 362: 362–369